专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08153111B2 Photo-triggered release of active substances from dendrimer-photosensitizer complexes 失效
标题翻译：从树枝状大分子光敏剂复合物照片触发释放活性物质
公开(公告)号：US08153111B2
公开(公告)日：2012-04-10
申请号：US10871676
申请日：2004-06-18
申请人： Volker Albrecht , Arno Wiehe , Beate Roeder , Wolfgang Neuberger
发明人： Volker Albrecht , Arno Wiehe , Beate Roeder , Wolfgang Neuberger
IPC分类号： A61K31/00 , A61K9/00
CPC分类号： A61K31/785 , A61K41/00 , A61K47/59 , A61K47/595 , Y10S424/16 , A61K2300/00
摘要： Compositions of dendrimer-photosensitizer complexes including therapeutic molecules, and methods for their synthesis and use are disclosed. The therapeutic molecules and the photosensitizers are each covalently attached to the dendrimer at its end-groups, essentially randomly. Upon exposure to radiation of a suitable wavelength, the photosensitizers are activated to break up the dendrimer structure and thus release the therapeutic molecules. In a preferred embodiment, the end-groups of the dendrimer are replaced with or covalently connected to therapeutic molecules and photosensitizers. In a further preferred embodiment, targeting molecules may also be attached to the dendrimer to create a more accurate treatment. The present invention is especially useful for medical applications, where therapeutic molecules can be delivered to body areas for treatment of a variety of diseases without risk of premature release in the body, due to the strength and stability of the bonds between the end-groups and the photosensitizers and therapeutic molecules.
摘要翻译：公开了包括治疗分子的树枝状大分子光敏剂复合物的组合物及其合成和使用的方法。治疗分子和光敏剂在其端基基本上随机共价连接到树枝状大分子。在暴露于合适波长的辐射下，激活光敏剂以分解树枝状聚合物结构，从而释放治疗分子。在优选的实施方案中，树枝状大分子的端基被治疗分子和光敏剂替代或共价连接。在另一个优选的实施方案中，靶向分子也可以连接到树枝状大分子以产生更准确的处理。本发明特别适用于医疗应用，其中治疗分子可以递送到身体区域以治疗各种疾病，而不会在体内过早释放的风险，这是由于端基之间的键的强度和稳定性光敏剂和治疗分子。

2. 发明申请

US20050281777A1 Photo-triggered release of active substances from dendrimer-photosensitizer complexes 失效
标题翻译：从树枝状大分子光敏剂复合物照片触发释放活性物质
公开(公告)号：US20050281777A1
公开(公告)日：2005-12-22
申请号：US10871676
申请日：2004-06-18
申请人： Volker Albrecht , Arno Wiehe , Beate Roeder , Wolfgang Neuberger
发明人： Volker Albrecht , Arno Wiehe , Beate Roeder , Wolfgang Neuberger
IPC分类号： A61K31/785 , A61K41/00 , A61K47/48
CPC分类号： A61K31/785 , A61K41/00 , A61K47/59 , A61K47/595 , Y10S424/16 , A61K2300/00
摘要： Compositions of dendrimer-photosensitizer complexes including therapeutic molecules, and methods for their synthesis and use are disclosed. The therapeutic molecules and the photosensitizers are each covalently attached to the dendrimer at its end-groups, essentially randomly. Upon exposure to radiation of a suitable wavelength, the photosensitizers are activated to break up the dendrimer structure and thus release the therapeutic molecules. In a preferred embodiment, the end-groups of the dendrimer are replaced with or covalently connected to therapeutic molecules and photosensitizers. In a further preferred embodiment, targeting molecules may also be attached to the dendrimer to create a more accurate treatment. The present invention is especially useful for medical applications, where therapeutic molecules can be delivered to body areas for treatment of a variety of diseases without risk of premature release in the body, due to the strength and stability of the bonds between the end-groups and the photosensitizers and therapeutic molecules.
摘要翻译：公开了包括治疗分子的树枝状大分子光敏剂复合物的组合物及其合成和使用的方法。治疗分子和光敏剂在其端基基本上随机共价连接到树枝状大分子。在暴露于合适波长的辐射下，激活光敏剂以分解树枝状聚合物结构，从而释放治疗分子。在优选的实施方案中，树枝状大分子的端基被治疗分子和光敏剂替代或共价连接。在另一个优选的实施方案中，靶向分子也可以连接到树枝状大分子以产生更准确的处理。本发明特别适用于医疗应用，其中治疗分子可以递送到身体区域以治疗各种疾病，而不会在体内过早释放的风险，这是由于端基之间的键的强度和稳定性光敏剂和治疗分子。

3. 发明申请

US20120101427A1 NOVEL PHOTOSENSITIZER FORMULATIONS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：用于口腔管理的新型光敏剂配方
公开(公告)号：US20120101427A1
公开(公告)日：2012-04-26
申请号：US13266056
申请日：2009-04-28
申请人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
发明人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
IPC分类号： A61M37/00 , A61K31/498 , C07D487/22 , C07D241/46 , A61K9/127 , A61K38/02 , A61K31/7056 , A61K31/706 , A61K31/79 , A61P35/00 , A61P17/00 , A61P9/00 , A61P19/02 , A61P31/04 , A61P33/02 , A61P31/12 , A61P31/00 , A61K31/409 , B82Y5/00
CPC分类号： A61K31/122 , A61K31/40 , A61K31/498 , A61K41/0071
摘要： The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic, antiviral, antiprionic and PDT treatments for diagnostic and therapeutic purposes. In a preferred embodiment the oral drug formulation comprises a photosensitizer and suitable excipients and may be administered in multiple doses over an extended period of time with exposure to activating radiation occurring generally between individual doses or in a light-independent manner. In another preferred embodiment PDT methods for treating hyperplasia and neoplasia, for localizing hyperplasic and neoplasic tissues and pathogen bacteria by fluorescence, for treating infections caused by pathogen bacteria in complex body fluids and for fat reduction, skin disorders and vascular diseases are provided.
摘要翻译：本发明提供用于口服给药以用于各种医学应用的新型药物制剂，包括用于诊断和治疗目的的抗癌，抗转移，抗细菌，抗真菌，抗原生动脉，抗病毒，抗细胞和PDT治疗。在优选的实施方案中，口服药物制剂包含光敏剂和合适的赋形剂，并且可以在延长的时间段内以多个剂量施用，暴露于通常在单独剂量之间或以轻轻独立的方式发生的活化辐射。在另一个优选实施方案中，提供了用于治疗增生和瘤形成的PDT方法，用于通过荧光定位超基质和新生组织和病原体细菌，用于治疗复杂体液中由病原体引起的感染和用于减脂，皮肤病和血管疾病。

4. 发明授权

US09315510B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT 有权
标题翻译：用于PDT的不对称内消旋卟啉和二氢卟酚的方法和应用
公开(公告)号：US09315510B2
公开(公告)日：2016-04-19
申请号：US13119907
申请日：2009-09-17
申请人： Arno Wiehe , Daniel Aicher , Christian B. W. Stark , Volker Albrecht , Susanna Gräfe
发明人： Arno Wiehe , Daniel Aicher , Christian B. W. Stark , Volker Albrecht , Susanna Gräfe
IPC分类号： A61K31/409 , C07D487/22 , C07H15/26
CPC分类号： C07D487/22 , C07H15/26
摘要： Biologically active compounds are provided that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. In another embodiment a method to reductively cleave the osmate(VI)ester avoiding the use of gaseous H2S is provided. In another embodiment substituents are identified that via their steric and/or electronic influence direct the dihydroxylation or reduction with diimine so that one isomer is favored. Another embodiment consists of formulate the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like solubility problems or delayed pharmacokinetics of the tetrapyrrole systems.
摘要翻译：提供了可用作诊断和治疗应用的光敏剂的生物活性化合物，特别是用于癌症，感染和其它过度增生性疾病的PDT，荧光诊断和PDT治疗非肿瘤适应症如关节炎，炎性疾病，病毒或细菌感染，皮肤病学，眼科学或泌尿系统疾病，以及提供以药物质量获得它们的方法。一个实施方案由合成具有定义的内消旋取代基排列的卟啉的方法组成，然后通过二羟基化或还原将该卟啉体系转化为二氢卟酚体系，并且如果形成多于一种的异构体，则通过色谱法分离，或者在正常或反向相二氧化硅。在另一个实施方案中，选择卟啉上的取代基以指导还原或二羟基化为二氢卟酚，从而选择性地形成某种异构体。另一个实施方案是提供具有更高膜亲和力和增加的PDT功效的两亲化合物。在另一个实施方案中，提供了避免使用气态H 2 S的还原性裂解锇酸酯（VI）酯的方法。在另一个实施方案中，鉴定了取代基，通过它们的空间和/或电子影响直接使二羟基化或还原与二亚胺，使得一种异构体是有利的。另一个实施方案包括将所需的异构体配制成待注射的脂质体制剂，避免不期望的作用，如四吡咯体系的溶解性问题或延迟的药代动力学。

5. 发明授权

US09308185B2 Glyco-substituted dihydroxy-chlorins and β-functionalized chlorins for anti-microbial photodynamic therapy 有权
标题翻译：糖基取代的二羟基二氢卟酚和用于抗微生物光动力治疗的功能性二氢卟酚
公开(公告)号：US09308185B2
公开(公告)日：2016-04-12
申请号：US13189113
申请日：2011-07-22
申请人： Daniel Aicher , Volker Albrecht , Burkhard Gitter , Christian B. W. Stark , Arno Wiehe
发明人： Daniel Aicher , Volker Albrecht , Burkhard Gitter , Christian B. W. Stark , Arno Wiehe
IPC分类号： C07H15/26 , A61K31/409 , A61K31/185 , A61K31/19 , A61K31/7056 , A61K41/00 , A61K47/48
CPC分类号： A61K31/185 , A61K31/19 , A61K31/409 , A61K31/7056 , A61K41/0071 , A61K47/549 , C07H15/26
摘要： Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The conjugates are of the class of compounds of dihydroxychlorins or β-functionalized chlorins connected to carbohydrate moieties and having the general formula
摘要翻译：提供了用于治疗和预防人和动物中致病微生物引起的感染性疾病的抗微生物分子缀合物。缀合物是与碳水化合物部分连接的二羟基二氢卟酚或二官能化二氢卟酚的化合物，具有通式

6. 发明申请

US20120263625A1 GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY 有权
标题翻译：用于抗微生物光化学治疗的GLYCO取代的二羟基氯和ß-功能氯化物
公开(公告)号：US20120263625A1
公开(公告)日：2012-10-18
申请号：US13189113
申请日：2011-07-22
申请人： Daniel Aicher , Volker Albrecht , Burkhard Gitter , Christian B. W. Stark , Arno Wiehe
发明人： Daniel Aicher , Volker Albrecht , Burkhard Gitter , Christian B. W. Stark , Arno Wiehe
IPC分类号： C07H15/26 , A61L2/08
CPC分类号： A61K31/185 , A61K31/19 , A61K31/409 , A61K31/7056 , A61K41/0071 , A61K47/549 , C07H15/26
摘要： Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is connecting dihydroxychlorins or β-functionalized chlorins to carbohydrate moieties. These conjugates are found to be very effective in combating bacterial infections caused by Gram-positive and Gram-negative bacteria, including their resistant strains. Significantly, they are also effective in complex environments, including blood, serum, and other body fluids which are present in patient's body. A method of use to control pathogenic microorganisms in human and animals is also provided.
摘要翻译：提供了用于治疗和预防人和动物中致病微生物引起的感染性疾病的抗微生物分子缀合物。这些缀合物的关键是将二羟基二氢卟酚或二官能化的二氢卟酚连接到碳水化合物部分。发现这些缀合物对抗革兰氏阳性和革兰氏阴性细菌（包括其抗性菌株）引起的细菌感染是非常有效的。值得注意的是，它们在复杂的环境中也是有效的，包括血液，血清和患者体内存在的其他体液。还提供了用于控制人和动物中的病原微生物的方法。

7. 发明申请

US20110142948A1 Nanoparticle Carrier Systems based on Human Serum Albumin for Photodynamic Therapy 有权
标题翻译：基于人血清白蛋白的纳米粒子载体系统用于光动力疗法
公开(公告)号：US20110142948A1
公开(公告)日：2011-06-16
申请号：US12941350
申请日：2010-11-08
申请人： Klaus Langer , Matthias Wacker , Beate Röder , Annegret Preuss , Volker Albrecht , Susanna Gräfe , Arno Wiehe , Hagen von Briesen , Karin Löw , Sylvia Wagner
发明人： Klaus Langer , Matthias Wacker , Beate Röder , Annegret Preuss , Volker Albrecht , Susanna Gräfe , Arno Wiehe , Hagen von Briesen , Karin Löw , Sylvia Wagner
IPC分类号： A61K31/409 , A61K9/00 , A61K9/14 , A61P35/00 , A61P17/00 , A61P27/02 , A61P13/00 , A61P19/02 , A61P29/00 , A61P31/04 , B82Y5/00
CPC分类号： A61K31/409 , A61K9/5169 , A61K41/0071
摘要： Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
摘要翻译：提供了在储存中稳定的组合物以及用于光动力疗法的药物基纳米颗粒制剂的制备方法，其包括疏水性光敏剂，人血清白蛋白（HSA）和稳定剂。这些纳米颗粒制剂提供用于胃肠外给药的治疗有效量的光敏剂（PS）。特别地，四吡咯衍生物可以用作光敏剂，其功效和安全性通过这样的纳米颗粒制剂增强。还提供了在无菌条件下制备基于HSA的纳米颗粒的方法。在本发明的一个优选实施方案中，一种疏水性PS被配制成用于肠胃外给药的纳米颗粒。该制剂可用于治疗过度和肿瘤状况，炎症问题，更具体地涉及靶向肿瘤细胞。

8. 发明授权

US08956648B2 Calciumphosphate-based nanoparticles as carrier-systems for photodynamic therapy 有权
标题翻译：基于磷酸钙的纳米粒子作为光动力疗法的载体系统
公开(公告)号：US08956648B2
公开(公告)日：2015-02-17
申请号：US13140855
申请日：2009-12-18
申请人： Burkhard Gitter , Susanna Gräfe , Arno Wiehe , Volker Albrecht , Matthias Epple , Janine Schwiertz , Kathirvel Ganesan
发明人： Burkhard Gitter , Susanna Gräfe , Arno Wiehe , Volker Albrecht , Matthias Epple , Janine Schwiertz , Kathirvel Ganesan
IPC分类号： A61P35/00 , A61P31/04 , A61K9/14 , A61K31/5415 , B82Y5/00 , A61K9/51 , A61K41/00 , A61K49/00
CPC分类号： A61K9/5115 , A61K41/0057 , A61K41/0071 , A61K49/0093 , Y10S977/773
摘要： The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy. In another preferred embodiment, hydrophilic cationic and anionic photosensitizers, especially those of the phenazinium, phenothiazinium and xanthenes series have been found to inactive pathogen bacteria and are the preferred photosensitizers to be formulated in calcium phosphate nanoparticle formulations for antibacterial photodynamic therapy. In another embodiment, photosensitizing nanoparticle formulations are useful to locate cells, tissues or bacteria by using fluorescence imaging methods.
摘要翻译：本发明提供负载药物的光敏剂纳米颗粒制剂及其制备光动力疗法的方法，其包括疏水或亲水性光敏剂，纳米颗粒磷酸钙，在某些情况下，辅助试剂如稳定剂。本发明的基于磷酸钙的纳米颗粒制剂提供优异的储存稳定性和用于静脉内或局部给药的治疗有效量的光敏剂。在优选的实施方案中，四吡咯衍生物如卟啉，二氢卟酚和细菌二氢卟酚是拟配制在用于光动力学肿瘤治疗的磷酸钙纳米颗粒制剂中的优选的疏水性光敏剂。另外，5,10,15,20-四（4-膦酰氧基苯基）卟吩（pTPPP）是用于光动力学肿瘤治疗的优选亲水性光敏剂。在另一个优选的实施方案中，已经发现亲水性阳离子和阴离子光敏剂，特别是吩嗪鎓，吩噻嗪和呫吨系列的亲水性阳离子和阴离子光敏剂是无活性的病原体细菌，并且是配制在用于抗菌光动力学治疗的磷酸钙纳米颗粒制剂中的优选的光敏剂。在另一个实施方案中，光敏纳米颗粒制剂可用于通过使用荧光成像方法定位细胞，组织或细菌。

9. 发明申请

US20110257586A1 CALCIUMPHOSPHATE-BASED NANOPARTICLES AS CARRIER-SYSTEMS FOR PHOTODYNAMIC THERAPY 审中-公开
标题翻译：基于钙磷酸盐的纳米颗粒作为光化学治疗的载体系统
公开(公告)号：US20110257586A1
公开(公告)日：2011-10-20
申请号：US13140855
申请日：2009-12-18
申请人： Burkhatd Gitter , Susanna Grafe , Arno Wiehe , Volker Albrecht , Matthias Epple , Janine Schwiertz , Kathirvel Ganesan
发明人： Burkhatd Gitter , Susanna Grafe , Arno Wiehe , Volker Albrecht , Matthias Epple , Janine Schwiertz , Kathirvel Ganesan
IPC分类号： A61M37/00 , A61K31/409 , A61K31/675 , A61P35/00 , A61P31/04 , A61K9/14 , A61K31/5415 , B82Y5/00
CPC分类号： A61K9/5115 , A61K41/0057 , A61K41/0071 , A61K49/0093 , Y10S977/773
摘要： The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy. In another preferred embodiment, hydrophilic cationic and anionic photosensitizers, especially those of the phenazinium, phenothiazinium and xanthenes series have been found to inactive pathogen bacteria and are the preferred photosensitizers to be formulated in calcium phosphate nanoparticle formulations for antibacterial photodynamic therapy. In another embodiment, photosensitizing nanoparticle formulations are useful to locate cells, tissues or bacteria by using fluorescence imaging methods.
摘要翻译：本发明提供负载药物的光敏剂纳米颗粒制剂及其制备光动力疗法的方法，其包括疏水或亲水性光敏剂，纳米颗粒磷酸钙，在某些情况下，辅助试剂如稳定剂。本发明的基于磷酸钙的纳米颗粒制剂提供优异的储存稳定性和用于静脉内或局部给药的治疗有效量的光敏剂。在优选的实施方案中，四吡咯衍生物如卟啉，二氢卟酚和细菌二氢卟酚是拟配制在用于光动力学肿瘤治疗的磷酸钙纳米颗粒制剂中的优选的疏水性光敏剂。另外，5,10,15,20-四（4-膦酰氧基苯基）卟吩（pTPPP）是用于光动力学肿瘤治疗的优选亲水性光敏剂。在另一个优选的实施方案中，已经发现亲水性阳离子和阴离子光敏剂，特别是吩嗪鎓，吩噻嗪和呫吨系列的亲水性阳离子和阴离子光敏剂是无活性的病原体细菌，并且是配制在用于抗菌光动力学治疗的磷酸钙纳米颗粒制剂中的优选的光敏剂。在另一个实施方案中，光敏纳米颗粒制剂可用于通过使用荧光成像方法定位细胞，组织或细菌。

10. 发明授权

US09211283B2 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy 有权
标题翻译：基于人血清白蛋白的纳米粒子载体系统进行光动力学治疗
公开(公告)号：US09211283B2
公开(公告)日：2015-12-15
申请号：US12941350
申请日：2010-11-08
申请人： Klaus Langer , Matthias Wacker , Beate Röder , Annegret Preuss , Volker Albrecht , Susanna Gräfe , Arno Wiehe , Hagen von Briesen , Karin Löw , Sylvia Wagner
发明人： Klaus Langer , Matthias Wacker , Beate Röder , Annegret Preuss , Volker Albrecht , Susanna Gräfe , Arno Wiehe , Hagen von Briesen , Karin Löw , Sylvia Wagner
IPC分类号： A61K9/51 , A61K31/409 , A61K33/20 , A61K41/00
CPC分类号： A61K31/409 , A61K9/5169 , A61K41/0071
摘要： Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
摘要翻译：提供了在储存中稳定的组合物以及用于光动力疗法的药物基纳米颗粒制剂的制备方法，其包括疏水性光敏剂，人血清白蛋白（HSA）和稳定剂。这些纳米颗粒制剂提供用于胃肠外给药的治疗有效量的光敏剂（PS）。特别地，四吡咯衍生物可以用作光敏剂，其功效和安全性通过这样的纳米颗粒制剂增强。还提供了在无菌条件下制备基于HSA的纳米颗粒的方法。在本发明的一个优选实施方案中，一种疏水性PS被配制成用于肠胃外给药的纳米颗粒。该制剂可用于治疗过度和肿瘤状况，炎症问题，更具体地涉及靶向肿瘤细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式